Siddharth H. Sheth, D.O., MPH
Student in an Organized Health Care Education/Training Program
- Medicare participating
At a glance
- Medical school
- Lake Erie College of Osteopathic Medicine, Erie (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 115
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Lake Erie College of Osteopathic Medicine, Erie
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Student in an Organized Health Care Education/Training Program primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
- Rex Hospital Raleigh, NC
- Carolina East Medical Center New Bern, NC
- Unc Health Nash Rocky Mount, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 115
- Services billed
- 616
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 144 | 67 |
| Established patient office or other outpatient visit, 30-39 minutes | 122 | 58 |
| New patient office or other outpatient visit, 60-74 minutes | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Pittsburgh, PA | 69 |
| Mekinist (trametinib dimethyl sulfoxide) | 46 |
| Tafinlar (dabrafenib mesylate) | 46 |
| Lenvima (lenvatinib mesylate) | 35 |
| Prednisone Other prescribers in Pittsburgh, PA | 25 |
| Prochlorperazine Maleate Other prescribers in Pittsburgh, PA | 22 |
| Ondansetron Hcl Other prescribers in Pittsburgh, PA | 22 |
| Oxycodone Hcl Other prescribers in Pittsburgh, PA | 19 |
| Eliquis (apixaban) Other prescribers in Pittsburgh, PA | 12 |
| Gabapentin Other prescribers in Pittsburgh, PA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 14 payments worth $12,030 in total to this clinician.
| Coherus Oncology, Inc. | $8,535 |
|---|---|
| Eisai Inc. | $3,045 |
| Exelixis Inc. | $172 |
| Janssen Biotech, Inc. | $147 |
| Regeneron Pharmaceuticals, Inc. | $131 |
| Compensation for services other than consulting (speaking, faculty) | $7,125 |
|---|---|
| Consulting Fee | $2,910 |
| Travel and Lodging | $1,309 |
| Food and Beverage | $686 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Coherus Oncology, Inc. Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) LOQTORZI · Oncology | $7,125 |
| Eisai Inc. Jul 23, 2025 | Consulting Fee Lenvima · Oncology | $2,910 |
| Coherus Oncology, Inc. Nov 11, 2025 | Travel and Lodging LOQTORZI · Oncology · travel to Brooklyn, NY · in-kind | $471 |
| Coherus Oncology, Inc. Nov 11, 2025 | Travel and Lodging LOQTORZI · Oncology · travel to Brooklyn, NY · in-kind | $432 |
| Coherus Oncology, Inc. Nov 11, 2025 | Travel and Lodging LOQTORZI · Oncology · travel to Brooklyn, NY · in-kind | $364 |
| Coherus Oncology, Inc. Nov 11, 2025 | Travel and Lodging LOQTORZI · Oncology · travel to Brooklyn, NY | $42.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $4,177,356 in research payments for these studies, mostly to the institutions running them.
- Window of opportunity trial of pembrolizumab ± olaparib followed by definitive chemoradiation in locally advanced head and neck cancer
Merck Sharp & Dohme LLC - A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Janssen Research & Development, LLC - STUDY NAME#Tissue and plasma based changes of molecular response to pembrolizumab and olaparib in locally advanced HNSCC
Merck Sharp & Dohme LLC - NEOCOMBAT-XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-Wildtype Anaplastic Thyroid Cancer: a phase 1B study
Exelixis Inc. - Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Beone Medicines USA, Inc. · Completed · NCT03744468 - A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L interve…
Merck Sharp & Dohme LLC - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.